NOV 202
Alternative Names: NOV-202Latest Information Update: 03 Jun 2024
At a glance
- Originator Noviga Research
- Developer LIDDS; Noviga Research
- Class Antineoplastics; Small molecules
- Mechanism of Action Microtubule protein modulators; Tubulin modulators; Vascular disrupting agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Brain cancer; Cancer